Daily Intelligence Brief
Plaintiff Intake Concentrates in Depo-Provera and AFFF
Plaintiff-side intake concentrated the week’s filing pressure, with Depo-Provera (3140) leading at 94 complaints as Anapol Weiss filed 34 and Singleton Schreiber LLP remained among the docket’s top firms. AFFF Personal Injury (2873) followed with 73 filings, its filer roster headed by Krentsel & Guzman LLP and Napoli Shkolnik, underscoring sustained volume in the PFAS litigation. The next tier stayed tightly firm-driven: Talcum Powder (2738) added 34 filings with The Robinson Law Firm Prof Corp atop the filer list, while Suboxone (3092) logged 33 with Ketterer Browne & Davani LLC leading the roster. GLP-1 claims supplied another active channel as Ozempic (3094) received 28 filings, with Levin Papantonio the leading firm. See the full filing feed and firm-level breakdowns here.
Semaglutide Retraction Narrows NAION Evidence Record
An August 1 retraction withdrew a 2025 Retina publication addressing semaglutide and non-arteritic anterior ischemic optic neuropathy, changing the published literature record in Glucagon-like Peptide-1 Receptor Agonists Non-Arteritic Anterior Ischemic Optic Neuropathy Products Liability (3163). The notice identifies the withdrawn article but gives no explanation for the retraction. That development narrows the peer-reviewed material available to experts advancing or contesting general-causation opinions in the vision-loss litigation. Counsel will need to separate opinions supported by independent medical evidence from any analysis that treated the retracted publication as affirmative support.
New Dupixent Guidance Centers Diagnostic Chronology
A July 31 clinical editorial accompanying new expert guidance placed diagnosis, rather than a settled drug-causation theory, at the center of Dupixent CTCL (3180). The authors said reported cutaneous T-cell lymphoma cases during dupilumab treatment may reflect unmasking of pre-existing disease and urged adequate testing when clinical suspicion arises. They also described the supporting literature as variable and largely drawn from retrospective and pharmacovigilance sources, while noting the absence of a decisive randomized-trial signal. The guidance gives counsel a current framework to test whether diagnostic chronology, pre-treatment workups, and alternative disease explanations support or undermine individualized causation opinions.
Generated by LexGenius Feed. Signals sourced from PACER federal court dockets, FDA/OpenFDA adverse event database, Federal Register, PubMed, and Google News.
